OBJECTIVE: The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units. DESIGN: Observational, multicentre, longitudinal study using a retrospective review of medical records. SETTING: Six Primary Care Centres. PARTICIPANTS: Patients > 18 years, who began smoking cessation treatment between 1/01/2006 and 1/12/2008 with varenicline, bupropion or NRT were included in the analysis. CONTINUATION: Patient follow-up was conducted from time-baseline (day 1) and assessed at 6 and 12 months. MAIN VARIABLES: comorbidities, effectiveness (continuous abstinence) and pharmacological tolerability. STATISTICAL ANALYSIS: logistic regression models and Kaplan-Maier survival curves; P<.05. RESULTS: A total of 957 smokers treated with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the analysis. Mean age: 47.6 (11.3) years; 58.6% men. 32.0% of smokers attended due to physical dependence. Average duration of smoking: 19.5 (6.7) years. At 6 months, 61.2% (95% CI: 54.6-67.8%) of participants in the varenicline group continuously abstained from smoking compared with 56.9% (95% CI: 50.6-63.2%) in the bupropion group, and 52.3% (95% CI: 48.0-56.6%) in the NRT group; P=.003. At 12 months, the rate of continuous abstinence was 57.4% (95% CI: 50.7-64.1%) in the varenicline group compared with 52.9% (95% CI: 46.6-59.2%) in the bupropion group and 47.1% (95% CI: 42.8-51.4%) in the NRT group; P=.002. CONCLUSION: One year-follow up results suggest that varenicline is an appropriate alternative compared with bupropion and NRT on smoking cessation in the PC setting.
OBJECTIVE: The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units. DESIGN: Observational, multicentre, longitudinal study using a retrospective review of medical records. SETTING: Six Primary Care Centres. PARTICIPANTS: Patients > 18 years, who began smoking cessation treatment between 1/01/2006 and 1/12/2008 with varenicline, bupropion or NRT were included in the analysis. CONTINUATION: Patient follow-up was conducted from time-baseline (day 1) and assessed at 6 and 12 months. MAIN VARIABLES: comorbidities, effectiveness (continuous abstinence) and pharmacological tolerability. STATISTICAL ANALYSIS: logistic regression models and Kaplan-Maier survival curves; P<.05. RESULTS: A total of 957 smokers treated with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the analysis. Mean age: 47.6 (11.3) years; 58.6% men. 32.0% of smokers attended due to physical dependence. Average duration of smoking: 19.5 (6.7) years. At 6 months, 61.2% (95% CI: 54.6-67.8%) of participants in the varenicline group continuously abstained from smoking compared with 56.9% (95% CI: 50.6-63.2%) in the bupropion group, and 52.3% (95% CI: 48.0-56.6%) in the NRT group; P=.003. At 12 months, the rate of continuous abstinence was 57.4% (95% CI: 50.7-64.1%) in the varenicline group compared with 52.9% (95% CI: 46.6-59.2%) in the bupropion group and 47.1% (95% CI: 42.8-51.4%) in the NRT group; P=.002. CONCLUSION: One year-follow up results suggest that varenicline is an appropriate alternative compared with bupropion and NRT on smoking cessation in the PC setting.
Authors: J R Banegas Banegas; L Díez Gañán; F Rodríguez-Artalejo; J González Enríquez; A Graciani Pérez-Regadera; F Villar Alvarez Journal: Med Clin (Barc) Date: 2001-12-01 Impact factor: 1.725
Authors: C A Jiménez Ruiz; M Barrueco Ferrero; S Solano Reina; M Torrecilla García; F Domínguez Grandal; J L Díaz-Maroto Muñoz; J Alonso Moreno; E de La Cruz Amorós Ed; R Abengozar Muela Journal: Arch Bronconeumol Date: 2003-01 Impact factor: 4.872
Authors: Carlos A Jiménez-Ruiz; Juan Antonio Riesco Miranda; Angela Ramos Pinedo; Miguel Barrueco Ferrero; Segismundo Solano Reina; José Ignacio De Granda Orive; Jesús Grávalos Guzmán; Lourdes Ramos Casado; Alfonso Pérez Trullén; Karl O Fagerström Journal: Arch Bronconeumol Date: 2008-04 Impact factor: 4.872
Authors: J Fernández de Bobadilla Osorio; C Sánchez-Maestre; M Brosa Riestra; O Arroyo; V Sanz de Burgoa; K Wilson Journal: An Med Interna Date: 2008-07
Authors: Kari Linden; Vesa Jormanainen; Miika Linna; Harri Sintonen; Koo Wilson; Teija Kotomäki Journal: Curr Med Res Opin Date: 2010-03 Impact factor: 2.580
Authors: Lieven Annemans; Kristiaan Nackaerts; Pierre Bartsch; Jacques Prignot; Sophie Marbaix Journal: Clin Drug Investig Date: 2009 Impact factor: 2.859
Authors: Carlos A Jiménez-Ruiz; Segismundo Solano-Reina; Jaime Signes-Costa; Eva de Higes-Martinez; José I Granda-Orive; José J Lorza-Blasco; Juan A Riesco-Miranda; Neus Altet-Gomez; Miguel Barrueco; Itziar Oyagüez; Javier Rejas Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-09-24